Targets for Cancer IO: A Deep Dive Series 2 is supported, in part, by educational grants from Genmab, US, Inc. Iovance Biotherapeutics, and Merck & Co., Inc. (as of 7/26/2022).Interested in supporting this program? The SITC Development team would love to work with you. Contact Development@sitcancer.org for more information on how your organization's support can help advance cancer immunotherapy and make "cure" a reality.
#Tcells,#GastrointestinalCancers, #GenitourinaryCancers, #Leukemia, #Lymphoma, #LungCancers, #SITC, #AdoptiveCellTherapy, #CombinationTherapy, #TherapeuticAntibodies, #Vaccines, #Cytokines, #ImmuneCheckpointInhibitors, #Clinician, #Oncologist, #PrimaryCarePhysician, #AlliedHealth, #Biomarkers
Meeting: 2022 Targets in Cancer IO: A Deep Dive in iPSC Cell Derived Therapies; Moderators: Jeffrey S. Miller, MD – University of Minnesota, Kalle Malmberg, MD, PhD – Oslo University Hospital; Presenters: Ran Jing, PhD - Boston Children’s Hospital, Sjouke van der Stegen, PhD - Memorial Sloan Kettering; Date: September 26, 202201:53:10
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us